KR20120132646A - Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity - Google Patents
Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity Download PDFInfo
- Publication number
- KR20120132646A KR20120132646A KR1020110048869A KR20110048869A KR20120132646A KR 20120132646 A KR20120132646 A KR 20120132646A KR 1020110048869 A KR1020110048869 A KR 1020110048869A KR 20110048869 A KR20110048869 A KR 20110048869A KR 20120132646 A KR20120132646 A KR 20120132646A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mushroom mycelium
- antioxidant
- mushroom
- situation mushroom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 15
- 230000001965 increasing effect Effects 0.000 title description 9
- 241000001727 Tropicoporus linteus Species 0.000 title description 4
- 239000007788 liquid Substances 0.000 title description 2
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 100
- 239000000284 extract Substances 0.000 claims abstract description 52
- 230000036737 immune function Effects 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000012136 culture method Methods 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000006227 byproduct Substances 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 238000005273 aeration Methods 0.000 claims description 2
- 235000013405 beer Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 235000013379 molasses Nutrition 0.000 claims description 2
- 125000001477 organic nitrogen group Chemical group 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 11
- 239000002609 medium Substances 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 235000013402 health food Nutrition 0.000 abstract description 8
- 230000003712 anti-aging effect Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000009630 liquid culture Methods 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 239000013630 prepared media Substances 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 10
- 229920002498 Beta-glucan Polymers 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 229920001503 Glucan Polymers 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 244000025254 Cannabis sativa Species 0.000 description 8
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 8
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 8
- 235000009120 camo Nutrition 0.000 description 8
- 235000005607 chanvre indien Nutrition 0.000 description 8
- 239000011487 hemp Substances 0.000 description 8
- 230000002132 lysosomal effect Effects 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 150000004804 polysaccharides Chemical class 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 241000283086 Equidae Species 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 240000006794 Volvariella volvacea Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000002391 anti-complement effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229920000310 Alpha glucan Polymers 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- -1 antibiotics Chemical class 0.000 description 4
- 108010008730 anticomplement Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000367 immunologic factor Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 235000016976 Quercus macrolepis Nutrition 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000753 anti-hemolysin Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000289527 Cordyline terminalis Species 0.000 description 1
- 235000009091 Cordyline terminalis Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010022769 Glucan 1,3-beta-Glucosidase Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ZICIMKCNGGNJIZ-UHFFFAOYSA-N Hispidine Natural products C1=CC(OC)=CC=C1C(C1)=C(C=2C=C(OC)C(OC)=CC=2)CN2C1CCC2 ZICIMKCNGGNJIZ-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004551 cotton seed extract Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000010956 nickel silver Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/20—Culture media, e.g. compost
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/30—Accessories for use before inoculation of spawn, e.g. sterilisers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/40—Cultivation of spawn
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/50—Inoculation of spawn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05C—NITROGENOUS FERTILISERS
- C05C5/00—Fertilisers containing other nitrates
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05F—ORGANIC FERTILISERS NOT COVERED BY SUBCLASSES C05B, C05C, e.g. FERTILISERS FROM WASTE OR REFUSE
- C05F11/00—Other organic fertilisers
- C05F11/08—Organic fertilisers containing added bacterial cultures, mycelia or the like
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05F—ORGANIC FERTILISERS NOT COVERED BY SUBCLASSES C05B, C05C, e.g. FERTILISERS FROM WASTE OR REFUSE
- C05F11/00—Other organic fertilisers
- C05F11/10—Fertilisers containing plant vitamins or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 새로운 상황버섯 균사체 액체 배양 방법에 관한 것으로, 보다 상세하게는 항산화 및 노화방지 효과와 면역력 강화 효과를 크게 증대시킬 수 있는 상황버섯 균사체 배양 방법에 관한 것이다. 이를 위해 본 발명은 여러 천연물 중에서 산약(마) 추출물을 기존의 상황버섯 균사체 배양용 배지에 첨가하여 새롭게 배지를 제조하며, 제조된 배지를 고온고압 멸균 시킨 후 상황버섯 균사체를 접종하여 배양하는 것을 특징으로 한다. 또한 배양된 상황버섯 균사체의 추출물은 항산화 및 노화방지 효과, 면역기능이 기존의 상황버섯 균사체에 비하여 높은 특징이 있으므로, 상기 상황버섯 균사체 배양액 추출물을 이용하는 건강식품 제조방법을 제공한다. The present invention relates to a new situation mushroom mycelium liquid culture method, and more particularly, to a situation mushroom mycelium culture method that can greatly increase the antioxidant and anti-aging effect and the immunity enhancing effect. To this end, the present invention is to prepare a new medium by adding the acid extract (e) extract from the various natural products to the existing culture medium mushroom mycelium culture, incubated by inoculating the situation mushroom mycelium after sterilization of the prepared medium at high temperature and high pressure It is done. In addition, the extract of the cultured mushroom mushroom mycelium has an antioxidant and anti-aging effect, and immune function is higher than the existing mushroom mushroom mycelium, it provides a health food manufacturing method using the mushroom mushroom mycelium culture extract.
Description
본 발명은 새로운 상황버섯 균사체 액체 배양 방법에 관한 것으로, 보다 상세하게는 항산화 및 노화방지 효과와 면역력 강화 효과를 크게 증대시킬 수 있는 상황버섯 균사체 배양 방법에 관한 것이다. 이를 위해 본 발명은 여러 천연물 중에서 산약(마) 추출물을 기존의 상황버섯 균사체 배양용 배지에 첨가하여 새롭게 배지를 제조하며, 제조된 배지를 고온고압 멸균 시킨 후 상황버섯 균사체를 접종하여 배양하는 것을 특징으로 한다. The present invention relates to a new situation mushroom mycelium liquid culture method, and more particularly, to a situation mushroom mycelium culture method that can greatly increase the antioxidant and anti-aging effect and the immunity enhancing effect. To this end, the present invention is to prepare a new medium by adding the acid extract (e) extract from the various natural products to the existing culture medium mushroom mycelium culture, incubated by inoculating the situation mushroom mycelium after sterilization of the prepared medium at high temperature and high pressure It is done.
또한 배양된 상황버섯 균사체의 추출물은 항산화 및 노화방지 효과, 면역기능이 기존의 상황버섯 균사체에 비하여 높은 특징이 있으므로, 상기 상황버섯 균사체 배양액 추출물을 이용하는 건강식품 제조방법을 제공한다.
In addition, the extract of the cultured mushroom mushroom mycelium has an antioxidant and anti-aging effect, and immune function is higher than the existing mushroom mushroom mycelium, it provides a health food manufacturing method using the mushroom mushroom mycelium culture extract.
상황버섯은 소나무비늘버섯과(Hymenochaetaceae)에 속하는 버섯으로 목질진흙버섯(Phellius Linteus) 이라고 하며, 산뽕나무, 참나무, 밤나무, 상수리나무 등의 고목에서 자생하는 담자균류 버섯이다. Situation mushroom is a fungus belonging to the family Hypnenochaetaceae and is called Phellius Linteus. It is a fungal fungus that grows in old trees such as mulberry, oak, chestnut and oak.
상황버섯은 목질진흙버섯, 마른진흙버섯, 말똥진흙버섯, 검은진흙버섯, 낙엽소충버섯 등 크게 다섯가지로 분류되며, 우리나라에는 8종이 자생하고 있다.Situation mushrooms are classified into five types, such as woody mud mushrooms, dry mud mushrooms, horse mud mushrooms, black mud mushrooms, and deciduous fungus mushrooms.
버섯에는 면역을 높여주는 단백다당체라는 물질을 함유하고 있는데 여러종의 버섯중에서 상황버섯이라고 부르는 목질상황(뽕나무상황)이 가장 많은 단백다당체를 함유하고 있는 것으로 알려져 있다.Mushrooms contain a protein called polysaccharide that boosts immunity. Among the various mushrooms, the woody condition called mulberry is known to contain the most protein.
버섯류는 식용 뿐만 아니라 그 분류학적 특성으로 인해 의약품의 개발소재로써 많은 주목을 받아왔다. 그 결과 항생물질을 비롯하여 항변이원성 물질, 항콜레스테롤성 물질 등 여러 가지 생리활성을 나타내는 화합물들이 보고되었다. 또한 이들 저분자물질과 항암 면역활성을 갖는 다당류인 Lentinan, Krestin, Schizophyllan 등과 같은 항암제 개발에 이르기까지 활발한 연구가 진행되어 이들 균류가 생리활성물질의 자원으로써 각광을 받고 있다. Mushrooms have attracted much attention as a development material for pharmaceuticals not only for edible but also for their taxonomic characteristics. As a result, various biologically active compounds, such as antibiotics, anti-mutagenic substances and anti-cholesterol substances, have been reported. In addition, active researches have been conducted to develop anticancer drugs such as Lentinan, Krestin, and Schizophyllan, which are polysaccharides having low molecular weight and anticancer activity, and these fungi are attracting attention as a source of bioactive substances.
특히 린테우스 상황버섯(P. linteus)은 1968년 일본 국립암연구소에서 항종양 활성이 96.7%에 이르고 식용버섯 및 약용버섯 중 최고의 활성을 나타낸다는 발표 이후 많은 관심의 대상이 되었으며, 자실체의 인공재배법 및 균사체의 대량배양 기술의 상업화에 성공함에 따라 많은 연구가 진행되어 상황버섯의 다양한 생리활성 기능이 밝혀지고 있다. In particular, P. linteus has been the subject of great interest since the Japanese National Cancer Institute announced in 1968 that the antitumor activity reached 96.7% and the highest activity among edible mushrooms and medicinal mushrooms. As a result of the successful commercialization of mass culture technology of mycelium, many studies have been conducted to reveal various physiological activities of mushrooms.
지난 10여년간 린테우스 상황버섯의 암 억제 및 인체 면역 증가 기능에 대하여 많은 연구가 이루어졌고, 자연 자원으로부터 새로운 항암 물질의 개발을 위한 후보물질로써 전망이 밝아지고 있다. 또한 상황버섯이 기존의 화학 항암약물과 병용하였을 때 암 치료가 더욱 향상된다는 것에 관심이 증가하고 있다. In the last decade, much research has been conducted on the functions of cancer suppression and human immunity in the linteus mushrooms, and prospects for the development of new anticancer substances from natural resources are brightening. There is also increasing interest in improving cancer treatment when situation mushrooms are used in combination with existing chemotherapy drugs.
다른 전통적인 아시아계 의약품처럼 상황버섯의 일반적인 처방은 경험적인 사용에 기반을 두고 있고, 명확한 성분과 기능에 관한 자료가 결여되어 있어, 과학적인 근거와 안전성을 바탕으로 하는 서양 의학 시스템에 적용되지 못하고 있다. 결국 많은 과학자들이 최신의 바이오의약 기술을 이용하여 다양한 질병을 막아내는 상황버섯의 비밀을 파헤치고자 하였다. 이러한 연구들은 린테우스 상황버섯이 세포매개 또는 고유의 면역성을 자극하고, T 임파구, B 임파구, 자연살해세포, 수지상세포, 그리고 대식세포를 활성화시켜 면역 강화 또는 면역 조절 기능을 할 뿐 아니라 많은 종류의 실험동물 또는 인간 종양에 대한 직접적인 세포독성을 가지고 있는 것을 입증하고 있다.As with other traditional Asian medicines, the general prescription of situational mushrooms is based on empirical use and lacks data on specific ingredients and functions, making them difficult to apply to Western medical systems based on scientific evidence and safety. In the end, many scientists sought to uncover the secrets of situational mushrooms using state-of-the-art biopharmaceuticals to combat various diseases. These studies suggest that linteus circulating mushrooms stimulate cell-mediated or innate immunity, activate T lymphocytes, B lymphocytes, natural killer cells, dendritic cells, and macrophages to enhance immune or immune regulation, as well as many types of experiments. It has been demonstrated to have direct cytotoxicity against animal or human tumors.
이러한 결과로부터 린테우스 상황버섯의 암세포 전이 억제(anti-metastatic), 혈관신생 억제(anti-angiogenic), 그리고 항산화 특성이 증명되었고, 린테우스 상황버섯이 강력한 화학예방요법제(chemo-preventive agent) 또는 부가적인 화학요법제로써 항암 치료제의 가능성을 보여주었다.From these results, the anti-metastatic, anti-angiogenic, and antioxidant properties of Linteus S. mushrooms were demonstrated, and Linteus S. mushrooms were potent chemo-preventive agents or additional agents. Chemotherapy has shown the potential of anticancer drugs.
면역이란 인체가 외부의 침입을 효율적으로 막기 위한 생체 방어 군대라고 할 수 있으며, 이러한 생체내의 방어시스템을 이용하여 암을 비롯한 여러 가지 질병을 치료하는 것을 면역요법이라 한다. 면역기능을 수행하는 세포들로는 면역반응을 보조하고 암세포와 같은 이물질 세포의 파괴 및 면역 반응을 억제하는 T세포, 외부 물질이 침투하였을 때 이에 대항하기 위한 항체를 생산하는 B세포, 외부에서 들어온 바이러스와 같은 작은 이물질을 직접 소화 분해시키는 대식세포(Macrophage)와 바이러스와 어떤 암세포들을 직접적으로 인지하거나 파괴시키는 자연살해세포(NK cell)등이 있다. Immunity is a biological defense force for the human body to effectively prevent external invasion, and the treatment of various diseases including cancer using the defense system in vivo is called immunotherapy. Cells that perform immune function include T-cells that support the immune response and inhibit the destruction of foreign cells such as cancer cells and suppress the immune response, B-cells that produce antibodies to counteract foreign substances when invaded, viruses from outside Macrophage, which directly digests and digests small foreign bodies, and NK cells, which directly recognize or destroy viruses and certain cancer cells.
비특이적인 면역 증강제로서 생물학적반응조정제(Biological Response Modifiers, BRM)는 면역계를 자극하여 숙주의 생물학적 반응을 변화시킴으로써 여러 가지 생리학적 효과를 나타내는 물질이다. BRM은 숙주의 종양에 대한 면역 능력의 증강, 조정 또는 회복에 작용하는 물질, 종양세포의 악성전화를 감소시켜 분화를 촉진하는 물질, 항암제의 효과를 증강시키고 부작용을 경감시키는 물질, 암세포의 내성획득을 감소시키는 물질, 종양화 또는 전이를 억제하는 물질 등 다채로운 작용을 가진 것 들을 총망라하여 BRM의 범주에 포함시킨다.Biological Response Modifiers (BRMs) as nonspecific immune enhancers are substances that exert a variety of physiological effects by stimulating the immune system to alter the biological response of the host. BRM is a substance that acts to enhance, modulate or repair the host's immune capacity, reduces the malignant call of tumor cells, promotes differentiation, enhances the effects of anticancer agents and reduces side effects, and acquires cancer cell resistance. It is included in the category of BRMs with a wide range of actions, such as those that reduce toxicities and those that inhibit tumorigenization or metastasis.
BRM의 대표적인 버섯 유래 다당류의 항종양 기작은 여러 가지 학설이 제시되어 왔으나 현재까지는 B세포, T세포, 대식세포 및 NK세포의 활성화에 의해서 일어난다고 보고되고 있다. 베타-글루칸에 의해 유도된 IL-1과 TNF-알파 Th 전구세포 및 NK세포 등을 성숙, 분화시킨다. T세포 활성화에 의해 생성된 IL-2, IFN-감마 대식세포 활성화인자(MAF) 등은 세포독성 T세포(Tc), NK세포 및 대식 세포를 성숙시키거나 활성화시키며, 이들은 표적세포를 특이적 또는 비특이적으로 파괴시킨다.The antitumor mechanism of representative mushroom-derived polysaccharides of BRM has been suggested in various theories, but until now, it has been reported to be caused by the activation of B cells, T cells, macrophages and NK cells. IL-1 and TNF-alpha Th progenitor and NK cells induced by beta-glucan are matured and differentiated. IL-2, IFN-gamma macrophage activator (MAF), etc. produced by T cell activation mature or activate cytotoxic T cells (Tc), NK cells, and macrophages, which target or target cells. Destroy nonspecifically.
또 다른 경로는 대식세포 또는 보조 T세포로부터 분리된 IL-1과 TNF-알파의해 혈청 단백질의 증가 및 보체계의 활성화를 통하여 비특이적으로 세포상해성 대식세포를 유도하여 종양세포를 공격한다고 알려져있다.Another pathway is known to attack tumor cells by inducing cytotoxic macrophages nonspecifically through the increase of serum proteins and activation of the complement system by IL-1 and TNF-alpha isolated from macrophages or helper T cells.
린테우스 상황버섯은 항암치료를 함에 있어서 화학요법 및 방사성 치료로 인해 약해진 생체내의 여러 가지 기관들의 기능을 부활시키거나 면역기능을 활성화시키고 화학요법제의 치료에 따르는 구토, 체중 감소, 오심, 탈모등과 같은 부작용을 최소화시키며, 암부위의 절제수술과 같은 외과적인 처치로 생체내의 약해져 있는 면역기능을 강화시키고 외부로부터 침입한 이물질들과 암세포를 퇴치하는 중요한 역할을 하는 것으로 보고되고 있다.Linteus Situation mushrooms induce chemotherapy and radiotherapy to revive the function of various organs in the body weakened by chemotherapy and radiotherapy, activate immune function, vomiting, weight loss, nausea, and hair loss following chemotherapy treatment. The same side effects are minimized, and surgical treatments such as resection of cancerous sites are reported to play an important role in strengthening the weakened immune function in vivo and combating foreign substances and cancer cells that have been invaded from the outside.
최근 연구에 의하면 특히 소화기 계통의 암인 위암, 식도암, 십이지장암, 결장암, 직장암을 비롯한 간암수술 후 화학요법을 할 때 상황버섯을 병행하여 복용하면 면역기능을 항진시키며, 장출혈과 오장 기능을 활성화시키고 해독작용을 한다는 보고가 있다. Recent studies have shown that when taking chemotherapy after liver cancer, especially gastric cancer, esophageal cancer, duodenal cancer, colon cancer, and rectal cancer, which are cancers of the gastrointestinal system, taking a combination of situational mushrooms increases immune function, activates and detoxifies intestinal bleeding and intestinal function. It is reported that it works.
또한 암 세포주에 대하여 직접적인 세포 독성은 없었으나 고형암과 복수암을 유발한 마우스에 상황버섯 추출물을 투여한 시험군은 종양 저지율, 생존일 수 및 백혈구의 화학주성능이 모두 상승하였고, 면역세포의 증식과 사이토카인 생성능이 증가되었으며, 이러한 항암작용은 IL-6와 TNF-알파 생성 증가에 따른 면역활성에 기인하는 것으로 설명되고 있다. In addition, there was no direct cytotoxicity against cancer cell lines, but the test group administered with the situation mushroom extract to solid and ascites-induced mice showed increased tumor suppression rate, survival time, and white blood cell chemotactic performance, and immune cell proliferation. And cytokine production capacity has been increased, and this anticancer activity has been explained to be due to the increase of IL-6 and TNF-alpha production.
섬유육종 암세포(MCA-102)를 이식한 마우스에서 린테우스 상황버섯 자실체로부터 분리된 단백다당체를 투여할 경우 골수에서 유래한 수지상세포를 성숙된 상태로 분화를 촉진시켰으며, 이러한 수지상세포는 림프기관으로 이동하여 T 세포가 매개하는 항암 면역반응을 증가시키는 것이 입증되었다. In mice transplanted with fibrosarcoma cancer cells (MCA-102), the administration of the protein polysaccharide isolated from the linteus circulating mushroom fruiting body promoted the differentiation of dendritic cells derived from bone marrow into mature state. It has been demonstrated to migrate to increase the anticancer immune response mediated by T cells.
린테우스 상황버섯 유래의 단백다당체는 IFN-감마 같은 Th1 의존형 사이토카인의 생성을 증가시키고, Th2 조절 사이토카인 IL-4의 생성을 억제시켜, Th1 주도의 면역상태를 유도하게 되며, 체중감소와 같은 부작용 없이 암세포의 성장을 억제하는 효과를 나타내었다. Protein polysaccharides derived from Linteus Situation mushrooms increase the production of Th1-dependent cytokines such as IFN-gamma and inhibit the production of Th2-regulated cytokines IL-4, leading to Th1-driven immune states, and side effects such as weight loss. It showed no effect of inhibiting the growth of cancer cells.
많은 연구를 통하여 린테우스 상황버섯은 자연살해세포의 활성을 증가시키고, 면역반응을 보조하며, 암세포와 같은 항원 보유 세포의 파괴 및 면역반응을 지휘하는 T세포의 활성을 증가시킬 뿐만 아니라 외부 물질이 침투하였을 때 이에 대응하기 위한 물질을 생산하는 항체 생산을 하는 B세포의 활성을 몇 십 배로 증가시키는 작용을 하고 있다. 또한 생체 내에 이물질이 침입하면 최전방에서 싸우는 대식세포의 활성도 증가시킨다. 따라서 린테우스 상황버섯은 암을 공격하는 면역세포들을 활성화함으로써 부작용 없이 암세포의 성장 혹은 전이를 억제하는 작용을 하는 것이다. Through many studies, the linteus mushrooms increase the activity of natural killer cells, aid the immune response, destroy the antigen-bearing cells, such as cancer cells, and increase the activity of T cells that direct the immune response, as well as invading foreign substances. When it does, it acts to increase the activity of B cells that produce antibodies to produce substances to cope with this by several orders of magnitude. In addition, the invasion of foreign bodies in the body also increases the activity of the macrophages fighting in the forefront. Therefore, the linteus situation mushroom acts to inhibit the growth or metastasis of cancer cells by activating immune cells that attack cancer.
린테우스 상황버섯은 암세포의 극복하기 위한 면역 강화 기능과 함께 과도한 면역기능을 조절하는 기능도 동시에 가지고 있다. 린테우스 상황버섯 자실체의 물추출물이 알러지 자극에 반응하여 대하여 IgE 의존형 또는 비의존형으로 복강비만세포(peritoneal mast cell)에서 히스타민의 방출을 억제하였고, 세포내 cAMP의 농도 또는 칼슘 흡수가 증가되는 것을 보고하였다. Linteus Situation Mushroom has the ability to regulate excessive immune function as well as immune function to overcome cancer cells. The water extract of Linteus S. aureus fruiting body inhibited the release of histamine in peritoneal mast cells, either IgE dependent or independent, in response to allergic stimulation and reported an increase in intracellular cAMP concentration or calcium uptake. .
이 결과는 린테우스 상황버섯 열수추출물이 수동피부 아나필락시스(passive cutaneous anaphylaxis)와 히스타민에 의해 자극된 skyrocketing vascular permeability를 낮추어 조절하며, 마우스 알러지 반응모델에서 TNF-a 의해 유도된 ear swelling을 낮추고, 천식 또는 알러지성 비염의 과민성을 가라앉히는 결과들과 동일한 것이다. These results indicated that Linteus hydroponic hydrothermal extracts regulated passive cutaneous anaphylaxis and histamine-induced skyrocketing vascular permeability and lowered TNF-a-induced ear swelling in the mouse allergic response model. It is the same as the result of calming the irritability of sexual rhinitis.
린테우스 상황버섯은 마우스 실험에서도 그 효과가 인정된 혈당 강하작용이 있으며, 췌장의 기능을 높여 인슐린의 분비를 촉진하는데 작용하는 다당체, 단백다당체 및 RNA 복합체 등이 풍부하게 함유되어 있다. 그 밖에 췌장 기능 장애에 면역 기능 이상이 있을 때에는 베타-글루칸에 의해서 면역 기능이 부활되고, 과잉의 면역반응에 의해서 생산되는 인터루킨류를 조절하여, 췌장내 베타세포에 대한 자가면역 반응으로 생기는 제I형 당뇨병에 유효하다는 연구 결과가 보고되었다. Linteus situation mushrooms have a hypoglycemic effect, which has been recognized in mouse experiments, and is rich in polysaccharides, protein polysaccharides, and RNA complexes that increase the function of the pancreas to promote insulin secretion. In addition, when there is an immune dysfunction in pancreatic dysfunction, the immune function is restored by beta-glucan and the interleukin produced by an excessive immune response is regulated, resulting in an autoimmune response to beta cells in the pancreas. Studies have been reported to be effective for type diabetes.
린테우스 상황버섯에서 분리된 히스피딘은 superoxide anion radical, 과산화수소 등 활성산소를 제거하는 효능이 매우 우수하고, 자실체와 배양균사체의 열수 추출 및 에탄올 추출물 등은 지질과산화 억제 효과가 우수하여 항산화 활성에 유의한 효과가 있음이 보고되었다. Hispidine isolated from Linteus S. mushroom was very effective in removing free radicals such as superoxide anion radical and hydrogen peroxide, while hot water extraction and ethanol extract of fruiting bodies and cultured mycelium were excellent in inhibiting lipid peroxidation. It has been reported to be effective.
린테우스 상황버섯 추출물은 간 손상물질인 사염화탄소(CCl4)를 이용한 동물실험에서 지질과산화 억제능이 밝혀졌으며, 간 지질 대사의 개선효과와 간 기능 보호 효과가 있음이 보고되었다. 또한 알코올에 의해 유도된 간 손상 모델 동물실험에서도 린테우스 상황버섯 추출물 투여에 의해서 간 기능 지표가 유의성 있게 감소하였고, COX-2, iNOS 및 염증 반응과 관련된 사이토카인들의 발현이 감소하여 알코올성 간 손상에 대한 보호 활성에 효과가 있는 것으로 알려졌다. Linteus S. mushroom extract was found to inhibit lipid peroxidation in animal experiments using carbon tetrachloride (CCl4), a liver damage substance, and reported to improve liver lipid metabolism and protect liver function. In liver-induced liver injury model animal experiments, liver function index was significantly decreased by the administration of Linteus S. mushroom extract, and the expression of COX-2, iNOS and cytokines related to inflammatory response was decreased. It is known to be effective in protective activity.
또한 대장암과 방광암 등의 원인인 장내세균의 유해효소에 대한 저해작용이 있고, 신경세포 보호활성을 가지고 있어 뇌졸중, 치매 등의 뇌신경계 질환의 예방 및 치료에 효과가 있는 것으로 보고되었으며, 항염증 작용과 관절염 치료 및 예방에 효과가 있는 연구결과가 발표되었다. In addition, it has been shown to be effective in preventing and treating cerebral nervous system diseases such as stroke and dementia because it has an inhibitory effect on harmful enzymes of intestinal bacteria, which cause colorectal cancer and bladder cancer, and has neuroprotective activity. Research has been published that is effective in treating and preventing arthritis.
린테우스 상황버섯 에탄올 추출물을 농도별로 투여하고 진통효과를 관찰한 결과 매우 유의성 있는 통증 억제 효과를 나타내었으며, 고농도에서는 대조약물인 phenylbutazone과 비슷한 진통작용이 있음을 알 수 있었다.The ethanol extracts of linteus circumferential mushrooms were administered at different concentrations and the analgesic effects were observed. The high concentrations of analgesic effects were similar to those of the control phenylbutazone.
그 외에도 항 알레르기 효과, 혈압강하 효과, 항 세균성 및 항 바이러스 효과, 항 돌연변이 효과에 대한 논문이 보고되고 있다.In addition, papers have been reported on antiallergic effects, hypotensive effects, antibacterial and antiviral effects, and anti-mutant effects.
산소는 생명을 유지하는데 꼭 필요한 요소로써 인체에서 호흡이란 과정을 통해 몸 속에서 에너지를 만드는 데에 사용하지만 산소가 우리에게 에너지만 주는 것은 아니다. 산소는 체내에서 음식물과 결합하는 과정 중에 활성산소이라는 유해성 산소를 만드는데, 이 활성산소는 우리 몸에 질병을 일으키는 원인으로 작용하고 있으며, 최근에는 의학계가 인간 노화의 주범으로 활성산소를 지목하고 있다. Oxygen is essential to life and is used by the body to create energy in the body through the process of breathing, but oxygen does not only give us energy. Oxygen creates harmful oxygen called free radicals during the process of binding to food in the body, which is responsible for causing diseases in our body, and the medical community has recently pointed to free radicals as the main culprit of human aging.
보통 정상적인 산소는 우리 몸 속에서 약 100초 이상 머무르지만 불안정한 활성산소는 100만~10억분의 1초 동안 생겼다가 순식간에 없어지며, 반응성이 매우 강한 특성이 있다. 이런 활성산소들은 우리 몸의 기본단위인 세포의 세포막을 공격해서 원세포 기능을 상실하게 만들고, 세포 내에 있는 유전자를 공격해서 해당 세포의 재생도 못하도록 막는다. 이는 결국에는 신호전달체계를 망가뜨리거나 면역력을 떨어트려 당뇨병, 동맥경화, 암 등의 체내 질환으로 이어지게 된다. 또한 세포의 재생을 막기 때문에 노화를 유발 또는 촉진시키는 역할을 하고 있다. 이처럼 호흡하는 과정 중에서 생성되는 활성산소는 자외선이나 방사선, 농약, 살충제, 담배연기 등에 과다 노출될 때 체내에서 그 양이 급격하게 증가하게 된다. Normal oxygen stays in our body for about 100 seconds or more, but unstable free radicals occur for 1 million to 1 billionth of a second, and then disappear quickly, and have a very reactive characteristic. These free radicals attack the cell membranes of cells, the basic unit of our body, and cause the loss of proto-cell function. Eventually, this will damage the signaling system or compromise the immune system, leading to body diseases such as diabetes, arteriosclerosis and cancer. It also plays a role in inducing or promoting aging because it prevents cell regeneration. As such, free radicals generated during respiration are rapidly increased in the body when exposed to ultraviolet rays, radiation, pesticides, insecticides, and tobacco smoke.
활성산소는 반응성이 높기 때문에 주변의 어떤 물질들과도 쉽게 반응하며, 특히 생체의 주된 구성성분인 지질, 단백질, 핵산(DNA, RNA)들은 활성산소의 공격 대상이 되어 쉽게 산화적 손상을 입게 된다. 또한 활성산소는 세포 재생을 막기 때문에 특히 심혈관질환, 치매, 관절염, 백내장 등 퇴행성 질환과 관련이 깊다. 따라서 활성산소는 만병의 근원이자 노화를 촉진시키는 주범이 되며, 현대인의 질환 중 90%가 활성산소와 관련이 있다고 알려져 있다.Because reactive oxygen is highly reactive, it easily reacts with any substance around it. Especially, the major components of the living body, such as lipids, proteins, and nucleic acids (DNA, RNA), are subject to active oxygen attack and are easily oxidatively damaged. . In addition, active oxygen blocks cell regeneration, and therefore, is particularly associated with degenerative diseases such as cardiovascular disease, dementia, arthritis, and cataracts. Therefore, free radicals are the source of all diseases and the main culprit of promoting aging, and 90% of modern diseases are known to be related to free radicals.
이와 같이 활성산소의 독성으로부터 자신들을 보호할 수 있는 능력이 항산화 방어능력이며, 그 능력을 가지고 있는 물질이 항산화제이다. 즉 항산화제는 산소를 사용하는 생명체에서 산소로부터 생기는 활성산소에 의한 손상과 활성산소가 아닌 산소(예: 단일산소, 오존)에 의한 지질, 단백질, 핵산, 탄수화물의 손상들을 차단, 억제하거나 지연시키는 물질로 정의할 수 있다.As such, the ability to protect them from the toxicity of free radicals is the antioxidant defense ability, the substance that has the ability is an antioxidant. In other words, antioxidants block, inhibit or delay the damage caused by free radicals from oxygen in living organisms and the damage of lipids, proteins, nucleic acids, and carbohydrates by non-active oxygen (e.g., single oxygen, ozone). Can be defined as a substance.
모든 생명체는 탄생과 함께 성장 성숙하며 시간이 지남에 따라 생리적 기능이 감소하고 외부변화에 대한 적응력이 감소하고 스트레스에 대한 저항력이 떨어져서 종국적으로 사망에 이르게 되는데, 이러한 연령의 증가에 따른 일련의 변화를 노화라 지칭한다. 노화의 과정은 생물학적으로 생체 내에 고유한 과정으로 존재함과 더불어 부적절한 유해 환경에 의해 촉진되며 질병의 발생에 의해 더 촉진될 수 있다. All living things grow and mature with birth, and over time, their physiological function decreases, their ability to adapt to external changes and their resistance to stress falls, eventually leading to death. Called aging. The process of aging, as a biologically inherent process in vivo, is facilitated by an inappropriate hazardous environment and can be further facilitated by the occurrence of disease.
최근 고령화 사회가 도래함에 따라 노년기의 건강과 질병예방 및 치료를 위한 실버 식품산업이 고속 성장이 가능한 미래형 블루오션으로 자리매김할 것으로 기대됨에 따라 많은 기업들이 새로운 실버 기능식품의 연구개발을 진행하고 있다. 실버 식품 분야에서 가장 주목 받는 생리활성 기능으로는 면역기능 증진, 항산화, 그리고 항균 기능이라 할 수 있다.With the advent of an aging society, many companies are conducting research and development of new silver functional foods, as the silver food industry for the health and disease prevention and treatment of old age is expected to become a future blue ocean capable of rapid growth. . The most notable physiologically active functions in silver foods are immune function enhancement, antioxidant activity, and antibacterial function.
진흙버섯속에 속하는 상황(Phellinus linteus)은 자연계에서는 매우 희귀종으로 자실체를 구하기가 대단히 어려울 뿐만 아니라 균사체를 분리하여 인공 배양 하기도 매우 어려운 단점이 있다. 최근들어 자실체를 인공 배양에 성공했다는 보고는 있으나 그 진위가 불분명한 상태이며 항암면역증강제로써의 효과는 일찍이 드러났음에도 불구하고 대량 생산 기술개발은 국내외에서 아직 미진한 상태이므로 상황버섯의 대량생산이 가능한 새로운 생산공정 기술의 개발이 절실히 요구되고 있다. Phellinus linteus belongs to the genus Mud (Phellinus linteus) is a very rare species in nature, it is very difficult to obtain the fruiting body, it is also very difficult to separate the mycelium and artificial culture. Recently, it has been reported that the fruiting body has succeeded in artificial cultivation, but its authenticity is unclear, and although the effect as an anticancer enhancer has been revealed earlier, the development of mass production technology is still inadequate at home and abroad. Development of production process technology is urgently required.
산약(山藥)으로도 불리는 마는 어지러움과 두통, 진정, 체력보강, 담 제거 등 한방에서 알려진 효능만도 10여 가지에 달 할 정도로 예로부터 약용으로 널리 이용 돼 왔다. Horses, also called mountain drugs, have been widely used for medicinal purposes since they have dizziness, headache, sedation, stamina reinforcement, and phlegm removal.
마는 자양강장에 특별한 효험이 있고 소화 불량이나 위장장애, 당뇨병, 기침, 폐질환 등에도 효과가 두드러진다. 특히 신장 기능을 튼튼하게 하는 작용이 강해 원기가 쇠약한 사람이 오래 복용하면 좋다고 한다. The horse has a special effect on nourishing tonic and is effective in indigestion, gastrointestinal disorders, diabetes, cough, and lung diseases. In particular, the kidney function is strong, strong people with weakened energy is good to take longer.
마는 마과에 속하는 여러해살이풀로 중국이 원산지이며 우리나라와 일본, 대만 등지에 분포하는데 전국적으로 재배도 많이 하고 있다. 마는 구워서도 먹지만 날 것을 가늘게 썰거나 갈아서 먹는 게 일반적이다. 또 쪄 말려 가루를 내 먹기도 한다. 마에 함유된 효소는 열에 약하므로 생즙으로 먹는 것이 좋다고 한다. The perennial herb is a perennial herb that is native to China and is distributed in Korea, Japan, and Taiwan. Although roasted, they are eaten, but it is common to chop or grind raw food. You can also dry it and eat it. Enzymes contained in hemp are weak to heat, so it is better to eat it with fresh juice.
마는 혈관에 콜레스테롤이 쌓이는 것을 예방하는 좋은 식품으로 마에 함유된 사포닌이 콜레스테롤 함량을 낮춰 혈압을 내리게 하는 효능이 알려져 있다. Hemp is a good food that prevents the accumulation of cholesterol in blood vessels. Saponin in horses is known to lower blood pressure by lowering cholesterol content.
영양적 측면에서 마는 녹말과 당분이 많고 비타민 B, B2, C, 사포닌 성분도 함유돼 있다. 특히 마의 점액질에는 소화효소와 단백질의 흡수를 돕는 ‘무친’ 성분이 들어있다. 무친은 사람의 위점막에서도 분비되며 이것이 결핍되면 위궤양을 일으키는 원인이 된다. 따라서 마를 섭취함으로서 위궤양 예방 치료와 소화력 증진에도 도움이 된다. In terms of nutrition, hemp is rich in starch and sugar, and also contains vitamins B, B2, C, and saponin. Hemp mucosa contains mucin, a protein that helps digestive enzymes and proteins absorb. Muchin is also secreted from the human gastric mucosa, and its deficiency causes gastric ulcers. Therefore, the intake of hemp helps to prevent stomach ulcers and improve digestion.
또한 마에는 칼륨이 풍부한데 칼륨은 소금의 독을 해소하고 마의 다른 성분과 합작해서 췌장의 인슐린 분비를 촉진해서 세포에 영양분을 잘 공급하기 때문에 몸 전체의 건강을 증진하는 데 위대한 역할을 한다. In addition, hemp is rich in potassium, which plays a great role in improving the health of the entire body, as it dissolves the poisons of salt and works with other ingredients in the hemp to promote pancreatic insulin secretion to nourish the cells.
특히 당뇨병은 인슐린 부족으로 생기는 병이기 때문에 인슐린 분비를 촉진하는 마는 당뇨병을 예방, 치료하는 데 위대한 구실을 한다. 좀 쉽게 설명하자면 우리가 먹는 음식물은 간장에서 각종의 영양분으로 만들어져 고체화해 저장된다. 그 자체로 된 영양분이 세포에 공급될 때는 액체 포도당으로 바꿔지는데 세포에 흡수시키기 위해서는 췌장에서 분비되는 인슐린이 필요하게 된다. In particular, because diabetes is caused by insulin deficiency, horses that promote insulin secretion play a great role in preventing and treating diabetes. To put it simply, the food we eat is made from soy sauce, made from a variety of nutrients, which are solidified and stored. When its nutrients are supplied to cells, they are converted to liquid glucose, which requires insulin from the pancreas to be absorbed by the cells.
그런데 췌장이 약해지거나 병들면 인슐린이 분비 안 되기 때문에 몸 전체에 영양분이 공급되지 않아 전신이 허약해지고 그 액체(포도당)가 세포에 흡수가 되지 않기 때문에 오줌에 섞여서 몸 밖으로 나와 버린다. 그것이 바로 당뇨병이다. However, if the pancreas weakens or becomes sick, insulin is not secreted, so the body is not supplied with nutrients, and the body is weakened and the liquid (glucose) is not absorbed by the cells. That is diabetes.
따라서 마를 먹으면 마의 여러 성분으로 췌장이 강해지고 마의 칼륨이 인슐린 분비를 촉진해서 영양분이 몸의 각 세포에 잘 흡수되기 때문에 몸 전체가 강해지고 동시에 당뇨병도 치유되는 것이다. Therefore, when you eat horses, the pancreas is strengthened with various ingredients of horses, potassium of horses promotes insulin secretion, and nutrients are well absorbed by each cell of the body.
한편 최근 연구결과의 마의 뿌리에서 노화방지에 매우 효과가 높은 것으로 알려진 DHEA의 원료 다이오스게닌이 함유돼 있는 것으로 밝혀졌다. 이에 따라 이 성분을 활용한 건강식품 개발도 진행 중이다.
Recent studies have shown that the roots of hemp contain Diogenin, a source of DHEA, which is known to be very effective in preventing aging. Accordingly, the development of health food using this ingredient is also in progress.
본 발명의 목적은 항산화 및 노화억제 기능, 그리고 면역증진 기능이 향상된 상황버섯 균사체 배양방법을 제공하는 것이며, An object of the present invention is to provide a method for cultivating a situation mushroom mycelium improved antioxidant and anti-aging function, and immune enhancement function,
또 다른 측면은 상기 상황버섯 균사체를 이용한 건강식품의 제조 방법을 제공하는 것이다.
Another aspect is to provide a method for producing a health food using the situation mushroom mycelium.
본 발명의 일 측면은 항산화 및 노화억제 기능, 그리고 면역증진 기능이 우수한 상황버섯 균사체 배양방법을 제공한다.One aspect of the present invention provides a situation mushroom mycelium culture method excellent in antioxidant and aging inhibitory function, and immuno-promoting function.
이를 위하여 본 발명은 산약을 열수 추출하여 제조된 산약 추출물을 기존의 상황버섯 균사체 배양 배지 조성물과 혼합하여 상황버섯 배양배지를 준비한 후 상황버섯 종균을 접종하여 배양하는 것을 특징으로 하는 상황버섯 균사체 배양방법을 제공한다.To this end, the present invention is to prepare a situation mushroom culture medium by mixing the acid powder extract prepared by extracting the hot water with the existing mushroom mushroom mycelium culture medium composition, and then inoculated with mushroom mushroom spawn seed culture method To provide.
또한 상기의 방법으로 제조된 상황버섯 균사체 배양액에 물을 첨가하고 가열하여 추출하고, 여과 및 농축 단계를 거쳐 농축액을 제조하거나 건조 공정을 거쳐 분말화하여 건강식품의 원료로 제조하여, 분말, 음료, 환, 과립, 캡슐 등의 식품 형태로 가공하는 방법을 제공한다.
In addition, water is added to the cultured mushroom mycelium culture medium prepared by the above method, extracted by heating, the concentrate is prepared through filtration and concentration steps or powdered through a drying process to prepare a raw material of health food, powder, beverage, It provides a method for processing into food forms such as pills, granules, capsules.
상기 방법으로 배양된 상황버섯 균사체는 항산화 및 노화억제, 그리고 면역기능 증진 효능이 기존의 상황버섯 균사체에 비하여 높기 때문에 각종 질환 예방 및 치료를 위한 건강식품의 원료로 활용할 수 있다. 특히 노화 및 활성산소에 의해 발생하는 당뇨, 암, 관절염, 심장질환 등 질환과 세균 및 바이러스 등에 의한 감염성 질병의 예방에 탁월한 효과가 있으며, 노인층을 대상으로 한 실버 식품에 유용하게 활용될 수 있다.
Situation mushroom mycelium cultured by the above method can be used as a raw material of health food for the prevention and treatment of various diseases because the antioxidant and anti-aging, and immune function enhancement effect is higher than the existing situation mushroom mycelium. In particular, it has an excellent effect in preventing diseases such as diabetes, cancer, arthritis, heart disease caused by aging and free radicals, and infectious diseases caused by bacteria and viruses, and can be usefully used for silver food for the elderly.
도 1은 본 발명의 상황버섯 균사체 배양 방법 공정도.
도 2는 상황버섯 균사체의 항산화-자유라디칼 소거-효과 비교도
도 3은 상황버섯 균사체의 항보체 활성 비교도
도 4는 상황버섯 균사체의 대식세포 Lysosomal enzyme 활성 비교도1 is a process mushroom culture method of the situation mushroom mycelium of the present invention.
Figure 2 is a comparison of the antioxidant-free radical scavenging effect of the situation mushroom mycelium
Figure 3 is a comparison of anti-complement activity of the situation mushroom mycelium
Figure 4 is a comparison of macrophage Lysosomal enzyme activity of the situation mushroom mycelium
이하, 본 발명을 보다 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in more detail.
이를 위하여 본 발명은 산약을 열수 추출하여 제조된 산약 추출물을 기존의 상황버섯 균사체 배양 배지 조성물과 혼합하여 상황버섯 배양배지를 준비한 후 상황버섯 종균을 접종하여 배양하는 것을 특징으로 하는 상황버섯 균사체 배양방법을 제공한다.To this end, the present invention is to prepare a situation mushroom culture medium by mixing the acid powder extract prepared by extracting the hot water with the existing mushroom mushroom mycelium culture medium composition, and then inoculated with mushroom mushroom spawn seed culture method To provide.
상기 산약 추출물의 제조방법은 채취된 산약을 물로 깨끗이 세척하고, 길이 2~10cm 정도의 적절한 크기로 절단하여 추출용기에 투입하고, 그 중량의 1 내지 30배, 바람직하게는 5 내지 15배 부피의(w/v%) 정제수를 포함한 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 바람직하게는 물로, 30 내지 120℃, 바람직하게는 80 내지 100℃ 온도에서 0.5 내지 20시간, 바람직하게는 2시간 내지 15시간 동안 추출하는 단계; 상기 추출 단계를 약 1 내지 10회, 바람직하게는 2내지 7회 반복하는 단계; 이를 여과농축 및 건조시키는 단계를 통해 본 발명의 상황버섯 균사체 배양에 첨가하는 산약추출물을 제조할 수 있다. The method of preparing the extract of the acid extract is washed with water and collected in a suitable size of about 2 ~ 10cm in length and put into the extraction container, 1 to 30 times the weight, preferably 5 to 15 times the volume (w / v%) a solvent selected from water containing purified water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water, at a temperature of 30 to 120 캜, preferably 80 to 100 캜 for 0.5 to 20 hours. Preferably, 2 to 15 hours of extraction; Repeating the extraction step about 1 to 10 times, preferably 2 to 7 times; Through this step of filtration concentration and drying it can be prepared a powder extract to add to the situation mushroom mycelium culture of the present invention.
상황버섯 균사체 배양은 YM, Malt yeast extract, MCM, Synthetic? 배지 등 유기태 질소원이나 복합질소원이 함유된 배지를 사용할 수 있다. Situation mushroom mycelium cultures include YM, Malt yeast extract, MCM, Synthetic? A medium containing an organic nitrogen source or a complex nitrogen source such as a medium can be used.
탄소원은 균류에 있어서 탄수화물, 단백질, 지질, 핵산 등의 합성과 에너지 공급원으로서 균주의 생장에 필수적인 영양원으로 단당류인 D-glucose, D-mannose, 이당류인 Maltose, 인삼박추출물, 당밀, 맥주담금박 등과 같은 식품부산물도 이용가능하다. Carbon source is an essential source of nutrients for the growth and growth of carbohydrates, proteins, lipids, nucleic acids, etc. in fungi, and the monosaccharides D-glucose, D-mannose, disaccharides Maltose, ginseng extract, molasses, beer dipped food, etc. The same food by-products are also available.
질소원은 세포질을 구성하고 있는 주요성분의 합성에 필수적인 영양원으로 유기태질소원인 Cassamino acid와 Amino acid류인 L-alanine, L-glutamic acid, 복합질소원인 Peptone, Yeast extract, Tryptone, 무기태질소원인Potassium nitrate, Sodium nitrate, 식품부산물인 C.S.L(옥수수전분 침출액) 맥주효모추출물, 면실박추출물, 유청 등도 사용이 가능하다. Nitrogen sources are essential nutrients for the synthesis of the major components of the cytoplasm. Cassamino acid and Amino acids, L-alanine and L-glutamic acid, complex nitrogen sources, Peptone, Yeast extract, Tryptone, and inorganic nitrogen sources, Potassium nitrate, Sodium nitrate, CSL (corn starch leachate) beer yeast extract, cottonseed extract, whey, etc. can be used.
목질진흙버섯의 균사생장에 적합한 탄소원 농도 및 질소원과의 비율(Carbon/Nitrogen)은 탄소원(D-Glucose)의 농도 2~3%와 C/N비 15:1~30:1 범위가 적절하며, 특히 탄소원 (D-Glucose) 농도 2%일때 C/N비20:1에서 균사생장과 밀도가 양호하다.The carbon source concentration and ratio with nitrogen source (Carbon / Nitrogen) suitable for mycelial growth of woody mud mushrooms are appropriate in the range of 2 ~ 3% of carbon source (D-Glucose) and C / N ratio of 15: 1 ~ 30: 1. In particular, mycelial growth and density are good at C / N ratio of 20: 1 when the concentration of D-Glucose is 2%.
상황버섯의 균사생장 최적온도는 25~37?범위가 가장 적절하며, 균사생장에 적합한 최적 pH는 5.0~8.0범위이며, 통기량은 0.5~2.0 vvm, 교반속도는 50~200 rpm이 적절하다. The optimum temperature for mycelial growth is 25 ~ 37 °, and the optimum pH for mycelial growth is 5.0 ~ 8.0, 0.5 ~ 2.0 vvm for aeration, and 50 ~ 200 rpm for agitation speed.
본 발명은 상기의 제조방법으로 얻어진 상황버섯 균사체 추출물을 유효성분으로 함유하는 항산화 및 노화억제, 면역기능 증진 효능을 가진 건강기능식품을 제공한다.The present invention provides a health functional food having antioxidant and aging inhibitory effects and immune function enhancement effect, which contains the situation mushroom mycelium extract obtained as the active ingredient.
상기의 방법으로 제조된 상황버섯 균사체 배양액을 호모게나이저로 균질화시킨 후, 물을 첨가하고 가열하여 추출하고, 여과 및 농축 단계를 거쳐 농축액을 제조하거나 건조 공정을 거쳐 분말화하여 건강식품의 원료로 사용한다.After homogenizing the situation mushroom mycelium culture medium prepared by the above method with a homogenizer, adding water, heating and extracting, preparing a concentrated solution through filtration and concentration steps or powdering it through a drying process as a raw material of health food use.
본 발명의 상황버섯 균사체 추출물을 함유하는 항산화 및 노화억제, 면역기능 증진 건강식품은 총 중량에 대하여 상기 복합 식품 조성물을 0.1 내지 50 중% 포함한다. 그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 복용자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.Antioxidant and anti-aging, immune function enhancing health food containing the situation mushroom mycelium extract of the present invention comprises 0.1 to 50% by weight of the composite food composition based on the total weight. However, the composition as described above is not necessarily limited thereto, and may vary depending on the type and progression of the condition and disease of the user.
본 발명의 상황버섯 균사체 추출물을 함유하는 식품은 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. 본 발명에 따른 상황버섯 균사체 추출물을 함유하는 식품 조성물은, 각각 통상의 방법에 따라 환제, 과립제, 정제, 캡슐제, 음료 등의 형태로 제형화하여 사용될 수 있다. Food containing the mushroom mushroom mycelium extract of the present invention may further comprise a suitable carrier, excipient and diluent commonly used in the preparation of the composition. The food composition containing the situation mushroom mycelium extract according to the present invention can be used in the form of pills, granules, tablets, capsules, beverages and the like according to conventional methods, respectively.
본 발명의 상황버섯 균사체 추출물을 함유하는 조성물에 함유될 수 있는 담체, 부형제 및 희석제로는 락토오즈(lactose), 덱스트로즈, 수크로스(sucrose), 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. Carriers, excipients, and diluents that may be included in the composition containing the situation mushroom mycelium extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch , Acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil Can be mentioned. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
본 발명의 상황버섯 균사체 추출물의 사용량은 나이, 성별, 체중에 따라 달라질 수 있으나, 0.1 내지 100 mg/kg으로, 바람직하게는 1 내지 10 mg/kg을 일일 1회 내지 수회 투여할 수 있다. 또한 그 투여량은 투여경로, 질병의 정도, 성별, 체중, 나이 등에 따라서 증감될 수 있다. 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The amount of the situation mushroom mycelium extract of the present invention may vary depending on age, sex, and weight, but may be 0.1 to 100 mg / kg, preferably 1 to 10 mg / kg once or several times daily. The dosage may also be increased or decreased depending on the route of administration, degree of disease, sex, weight, age, and the like. Accordingly, the dosage is not limited in any way to the scope of the present invention.
본 발명의 상기 조성물 자체는 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있는 약제이다.Since the composition itself of the present invention has little toxicity and side effects, it is a medicament that can be used safely even when taken for a long time for the purpose of prevention.
본 발명의 상황버섯 균사체 추출물을 함유하는 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health functional beverage composition containing the mycelium mushroom mycelium extract of the present invention is not particularly limited to other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and various flavors or natural carbohydrates, such as ordinary drinks, may be used. It may contain as an additional component. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 복합 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물들은 천연 과일 쥬스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, the composite food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, and alginic acid. And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the extracts of the present invention may contain pulp for the production of natural fruit juices and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지는 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
These components may be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
상황버섯 균사체 배양Situation mushroom mycelium culture
경북 안동에서 재배된 산약을 물로 깨끗이 세척하여 건조하고, 100 g을 달아 추출용기에 투입한 후 정제수 10 L를 첨가하여 100℃ 온도에서 4시간 동안 추출하며, 이 과정을 3회 반복한다. 추출액을 모아 여과지로 여과한 후 분무 건조시켜 혼합 추출물 분말을 제조한다. 상기 과정을 통하여 얻어진 산약 추출물 분말 각각 1, 2, 4, 5 g과 포도당 4g, 효모추출물 4 g, 맥아추출물 10g을 혼합하여 정제수 1L에 녹인다.After washing with dry water cultivated in Andong, Gyeongbuk, dried, weigh 100 g, put it in the extraction container, add 10 L of purified water and extract it for 4 hours at 100 ℃. Repeat this process three times. The extract is collected, filtered through filter paper, and spray dried to produce a mixed extract powder. 1, 2, 4, and 5 g of the powder of the extract powder obtained through the above process, 4 g of glucose, 4 g of yeast extract, and 10 g of malt extract are dissolved in 1 L of purified water.
상기와 같이 조제된 배지를 121℃, 1.2기압하에서 15분간 멸균 후 전배양된 상황버섯 균사체 종균을 5%(v/v) 되게 접종한 후 30℃에서 7일간 배양하여 상황버섯 균사체 배양액을 제조한다.After sterilizing the medium prepared as described above at 121 ° C. and 1.2 atm for 15 minutes, the cultured mushroom mycelium seedlings were inoculated to 5% (v / v) and cultured at 30 ° C. for 7 days to prepare a situation mushroom mycelium culture medium. .
비교를 위하여 산약추출물을 첨가하지 않은 배지에도 동일한 조건으로 상황버섯 균사체를 접종하여 배양하여 비교군으로 사용한다.
For comparison, inoculated with mycelium mushroom mycelium under the same conditions in the medium without adding the extract, and used as a comparison group.
상황버섯 균사체 추출물 분말 제조Situation Mushroom Mycelia Extract Powder Preparation
상기의 방법으로 제조된 상황버섯 균사체 배양액을 호모게나이저로 균질화시킨 후, 물을 배양액 부피와 동일하게 첨가하고 100℃에서 3시간 가열하여 추출하고, 여과 및 농축 단계를 거쳐 진공 건조 공정을 거쳐 분말화한다.
After homogenizing the cultured mycelium mycelium culture medium prepared by the above method with a homogenizer, water was added in the same amount as the culture medium and heated and extracted at 100 ° C. for 3 hours, followed by filtration and concentration, followed by vacuum drying to obtain powder Make up.
상황버섯 균사체 추출물 분말의 베타-글루칸 함량 측정Determination of Beta-Glucan Content of Situary Mushroom Mycelia Extract Powder
베타-글루칸의 측정은 메가자임 β-글루칸 분석 키트(Megazyme β-glucan assay kit; Megazyme International Ireland Ltd., Ireland)를 이용하여 총 글루칸과 글루칸 이외의 당함량을 구한 후, 알파-글루칸과 글루칸 이외의 당함량의 값을 빼서 구하였다.Beta-glucan was measured by using a Megazyme β-glucan assay kit (Megazyme International Ireland Ltd., Ireland) to determine the sugar content other than total glucan and glucan, and then excluding alpha-glucan and glucan. Obtained by subtracting the value of sugar content.
각각의 0.5mm 크기 이하의 균사체 분말 100mg에 1.5mL 염산(37%, v/v)을 첨가 후, 내용물을 잘 섞어준 다음, 30℃에서 60분 동안 15분 간격으로 잘 섞어 주었다. 전분 및 단백질을 분해, 제거시키기 위하여 증류수 10mL씩을 첨가 후 2시간 동안 끓는 물(100℃)에 방치하였다.To 100 mg of mycelial powder of 0.5 mm or less, 1.5 mL of hydrochloric acid (37%, v / v) was added, and then the contents were mixed well, followed by mixing at 30 ° C. for 60 minutes at 15 minutes intervals. In order to decompose and remove starch and protein, 10 mL of distilled water was added thereto and then left in boiling water (100 ° C.) for 2 hours.
그 후, 실온에서 내용물을 식힌 후, 2N KOH를 첨가하여 pH를 맞추고, 200mM 소듐 아세테이트 완충액(sodium acetate buffer; pH 5.0)로 희석하였다. 희석된 내용물은 원심분리를 통해 상층액을 얻어 상층액 100μL에 엑소 3-β-글루카네이즈(exo-1,3-β-Glucanase; 100U/mL) + β-글루코시다아제(β-Glucosidase; 20 unit/mL) 용액을100μL씩 첨가하여 1시간 동안 40℃에서 방치하고, 글루코즈 측정 용액(glucose determination reagent) 3mL을 첨가한 후 40℃에서 20분 동안 방치하였다. 그 후, 510 nm에서 흡광도를 측정하여 총 글루칸과 글루칸 이외의 당 함량값을 얻었다. 또한 알파-글루칸과 글루칸 이외의 당함량값은 균사체분말 100mg에 2M KOH 2mL를 넣고 마그네틱바를 이용하여 얼음이 채워진 수욕에서 20분간 교반한 후에 1.2 M 소듐 아세테이트 완충액(Sodium acetate buffer; pH 3.8) 8mL를 첨가하였다.The contents were then cooled to room temperature, adjusted to pH by addition of 2N KOH, and diluted with 200 mM sodium acetate buffer (pH 5.0). The diluted contents were obtained by centrifugation to obtain supernatant, and then, 100 μL of supernatant, exo-1,3-β-Glucanase (100 U / mL) + β-glucosidase (β-Glucosidase; 20 unit / mL) solution was added at 100 μL and left at 40 ° C. for 1 hour, and 3 mL of glucose determination reagent was added and then left at 40 ° C. for 20 minutes. Thereafter, absorbance was measured at 510 nm to obtain a total glucan and sugar content values other than glucan. In addition, sugar content values other than alpha-glucan and glucan were added to 2 mg KOH 2mL in 100mg of mycelium powder, and stirred for 20 minutes in an ice-filled water bath using a magnetic bar, followed by 8mL of 1.2M sodium acetate buffer (pH 3.8). Added.
또한 아밀로글루코시다아제(Amyloglucosidase; 1,630 unit/mL) + 인버타아제(Invertase; 500 unit/mL) 용액을 200μL 첨가한 후, 40℃에서 30분 동안 방치하고, 200mM 소듐 아세테이트 완충액(sodium acetate buffer; pH 5.0)을 이용하여 희석하였다. 그 다음 글루코즈 측정 용액(glucose determination reagent) 3mL를 첨가한 후 20분 동안 40℃에서 방치하였다. 그 후 510nm에서 흡광도를 측정하여 알파-글루칸과 글루칸 이외의 당함량값을 얻었다.In addition, 200 μL of amyloglucosidase (1,630 unit / mL) + Invertase (500 unit / mL) solution was added, and then left at 40 ° C. for 30 minutes, and 200 mM sodium acetate buffer (sodium acetate buffer) ; pH 5.0). Then, 3 mL of glucose determination reagent was added and left at 40 ° C. for 20 minutes. The absorbance was then measured at 510 nm to obtain sugar content values other than alpha-glucan and glucan.
베타-글루칸 함량은 아래의 식을 통해 구했다.
Beta-glucan content was obtained by the following equation.
베타-글루칸 (%) = (총 글루칸 (%) + 글루칸 이외의 당(%)) - (알파-글루칸 (%) + 글루칸 이외의 당(%))
Beta-Glucan (%) = (Total Glucan (%) + Sugars other than Glucan (%))-(Alpha-Glucan (%) + Sugars other than Glucan (%))
산약 추출물 함량이 각각 0, 1, 2, 4, 5 g/L인 배지에서 배양된 상황버섯 균사체의 베타-글루칸 함량을 측정한 결과는 [표 1]과 같다.The results of measuring the beta-glucan content of the situation mushroom mycelium cultured in the medium of the extract powder of 0, 1, 2, 4, 5 g / L, respectively are shown in [Table 1].
산약추출물의 첨가량이 4 g/L가 될 때까지 상황버섯 균사체의 베타-글루칸 함량은 농도에 비례하여 증가하였으며, 그 이후에는 유사한 양상을 보였다.
The content of beta-glucan in the mushroom mycelium increased in proportion to the concentration until 4 g / L of the extract was added.
균 주division
Strain
항산화력 측정 Antioxidant Activity
상기 실시예 1의 각 배지 조건하에서 제조한 상황버섯 균사체 추출물을 사용하여 항산화력을 측정하였다. 산화적 생체 손상에 있어서 여러 가지 요인에 의해 생성된 자유라디칼(free radical)이 직접적인 매개체가 된다는 것이 밝혀졌다. 따라서, 전자공여 작용은 생체내에 생성된 활성 라디칼에 전자를 공여하여 안정된 화합물로 변환시킴으로써 활성 라디칼에 의한 생체손상을 억제하는 작용의 척도로 이용되고 있다.Antioxidant activity was measured using the situation mushroom mycelium extract prepared under each medium condition of Example 1. It has been found that free radicals produced by various factors in oxidative biological damage become direct mediators. Therefore, the electron donating action is used as a measure of the action of inhibiting bio damage by the active radicals by donating electrons to the active radicals generated in vivo and converting them into stable compounds.
그러므로 특정 물질의 자유 라디칼 소거 효과를 평가하기 위해서는, 그 물질이 디페닐피크릴히드라질(1,1-diphenyl-2-picrylhydrazyl, DPPH; Sigma) 분자에 전자를 공여하는 능력을 측정한다. DPPH는 매우 안정한 자유 라디칼 화합물로서 분자내의 비공유 전자에 의해 520 ㎚에서 빛을 흡수하여 진한 보라색을 띠는 물질이다. 외부에서 전자를 제공할 수 있는 물질이 가해져 DPPH의 비공유전자가 쌍을 이루게 되면 진한 보라색이 없어지므로 그 흡광도 차이를 이용하여 항산화 효과를 측정할 수 있어 항산화 활성 검정에 많이 이용되고 있다.Therefore, to assess the free radical scavenging effect of a particular substance, the substance is measured for its ability to donate electrons to diphenylpicrylhydrazyl (DPPH; Sigma) molecules. DPPH is a very stable free radical compound that absorbs light at 520 nm by non-covalent electrons in a molecule and is dark purple. When a substance capable of providing electrons from the outside is added to the pair of non-shared electrons of DPPH, the dark purple disappears. Therefore, the antioxidant effect can be measured using the difference in absorbance, which is widely used in antioxidant activity assays.
본 발명의 복합 식품 조성물의 전자공여능을 측정하기 위하여, 블로시(Blosi)의 방법에 따라 1.5×10-4 M DPPH 600 ㎕에 시료의 농도가 100, 50, 25 및 12.5 ㎕/㎖가 되도록 각각 가한 후 메탄올(methanol) 용액을 가하여 최종 부피를 3 ㎖로 만들었다. 이를 10초간 진탕하여 잘 섞은 후 520 ㎚에서 흡광도를 측정하여, 하기 수학식 2에 의해 DPPH 자유기의 소거 활성(Radical scavenging activity)을 산정하였다. 결과는 도 2에 나타내었다.In order to measure the electron donating ability of the composite food composition of the present invention, 600 μl of 1.5 × 10 −4 M DPPH according to the method of Blosi so that the concentration of the sample was 100, 50, 25 and 12.5 μl / ml, respectively. After addition, methanol solution was added to bring the final volume to 3 ml. After shaking for 10 seconds to mix well, absorbance was measured at 520 nm, and the scavenging activity of the DPPH free group was calculated by Equation 2 below. The results are shown in FIG.
[도 2]에 나타난 바와 같이 산약 추출물의 첨가 농도가 4 g/L인 배지에서 배양한 상황버섯 균사체 추출물이 가장 높은 항산화 활성을 보였다.
As shown in FIG. 2, the mycelial mushroom mycelium extract cultured in a medium having an added concentration of the extract of the fungus extract showed the highest antioxidant activity.
면역기능 증진 효과Immune function enhancement effect
보체들의 활성화에 미치는 영향을 파악하기 위하여 보체가 특이 항-적혈구항체(hemolysin)존재 하에서 적혈구를 용해(hemolysis)시킬 수 있다는 특성을 이용한 보체결합반응(complement fixation test) 이라는 항체 검사법을 이용하여서 보체의 활성화정도를 측정하고 있다. Normal human serum, GVB++ 그리고 sample을 동량 첨가하여 일차반응(37℃, 30 min)한 후 10-160배율로 희석한 다음 감작혈구를 첨가하고 2차 반응(37℃, 1 h)하여 감작혈구의 용혈 억제 정도를 흡광도 412 nm에서 측정한다.To understand the effects on the activation of complements, the complement test was performed using an antibody test called the complement fixation test, which uses the property that complement can dissolve erythrocytes in the presence of specific anti-hemolysin. The degree of activation is being measured. Normal human serum, GVB ++ and the same amount of sample was added to the primary reaction (37 ℃, 30 min) and diluted to 10-160 magnification, sensitized blood cells were added and the secondary reaction (37 ℃, 1 h) to sensitized blood cells The degree of hemolysis inhibition was measured at absorbance 412 nm.
항보체 활성이란 보체들의 활성화에 미치는 영향을 파악하기 위하여 보체가 특이 항-적혈구항체(hemolysin)존재 하에서 적혈구를 용해(hemolysis)시킬 수 있다는 특성을 이용한 보체결합반응(complement fixation test) 이라는 항체 검사법을 이용하여서 보체의 활성화 정도를 측정하고 있다. Anti-complement activity is an antibody test called the complement fixation test that uses the property that complement can hemolyze red blood cells in the presence of specific anti-hemolysin antibodies in order to determine the effect on complement activation. The degree of activation of complement is measured.
본 발명의 실시예 1에서 산약추출물 4g/L 배지에서 배양된 상황버섯 추출물의 시료 농도에 따른 항보체 효과를 측정한 결과는 [도 3]과 같다. 농도 의존적으로 항보체 활성도 증가함을 알 수 있었고, 1000 ㎍/㎖에서 최대활성을 나타내었다. 양성대조군으로 사용된 LPS (lipopolysaccharide) 와 비교하였을 때 저농도(100, 500 ㎎/㎖)에서는 낮은 활성을 보였지만, 고농도(1000 ㎎/㎖) 에서는 양성대조군 보다 높은 활성을 보였다. 이 결과로 미루어 보아 복합 조성물은 매우 높은 항보체활성을 가지는 것으로 사료된다.
In Example 1 of the present invention, the results of measuring the anti-complement effect according to the sample concentration of the situation mushroom extract cultured in 4g / L medium of the acid extract are as shown in FIG. It was found that anti-complement activity was increased in a concentration-dependent manner, and showed maximum activity at 1000 ㎍ / mL. Compared to the LPS (lipopolysaccharide) used as a positive control, it showed low activity at low concentrations (100, 500 mg / mL), but higher activity than the positive control at high concentrations (1000 mg / mL). As a result, the composite composition is considered to have a very high anticomplement activity.
대식세포의 Lysosomal enzyme 활성 측정Measurement of Lysosomal Enzyme Activity of Macrophages
Lysosomal enzyme과 식세포 (phagocyte)의 활성은 대식세포의 기능을 평가하는 중요한 요소이며, 단핵 식세포에 의한 lysosomal enzyme의 생성은 수많은 외래 자극물질에 반응하여 일어난다 (Page et al., 1978)고 알려져 있다. Lysosomal enzymes and phagocyte activity are important factors in evaluating macrophage function, and the production of lysosomal enzymes by monocytes occurs in response to numerous foreign stimulants (Page et al ., 1978).
Lysosomal enzyme 활성은 96-well flat-bottomed tissue culture plates를 이용하여 분석하였다 (Suzuki et al., 1990). 0.1% Triton X-100 25 ㎕를 첨가하여 microplate (2×105 cells/well) 내에서 대식세포 단층을 용해시켰다. 10 mM PNPP (p-nitrophenyl phosphate) 용액 150 ㎕를 대식세포의 lysosomal enzyme (acid phosphatase)의 반응기질로서 첨가하였다. 그 후, 50 ㎕ citrate buffer을 각 well에 첨가한 후, 37℃에서 1시간 동안 배양한 다음, 0.2 M borate buffer (pH 9.8) 25 ㎕를 반응 혼합물에 첨가하고, 405 nm에서 흡광도를 측정하였다. Lysosomal enzyme activity was analyzed using 96-well flat-bottomed tissue culture plates (Suzuki et al., 1990). 25 μl of 0.1% Triton X-100 was added to lyse the macrophage monolayer in the microplate (2 × 10 5 cells / well). 150 μl of 10 mM PNPP (p-nitrophenyl phosphate) solution was added as a reductant of lysosomal enzyme (acid phosphatase) of macrophages. Then, 50 μl citrate buffer was added to each well, followed by incubation at 37 ° C. for 1 hour, and then 25 μl of 0.2 M borate buffer (pH 9.8) was added to the reaction mixture, and the absorbance was measured at 405 nm.
본 발명의 실시예 1에서 산약추출물 4g/L 배지에서 배양된 상황버섯 추출물의 시료 농도에 따른 대식세포의 lysosomal enzyme 활성을 측정한 결과는 [도 4]와 같다. 대식세포의 lysosomal enzyme 활성은 균사체 추출물의 의 처리 농도가 높을수록 활성이 높게 나타났으며, 음성 대조군 (NC)과 비교했을 때, 상황버섯 균사체 추출물 10, 50 및 100 ㎍/ml 농도에서 각각의 효소 활성은 59.3, 68.9 및 102.9%로 각각 증가하였다.
The results of measuring the lysosomal enzyme activity of the macrophages according to the sample concentration of the mushroom extract incubated in 4g / L medium of the extract of the present invention in Example 1 are as shown in FIG. The lysosomal enzyme activity of macrophages was higher at higher concentrations of mycelial extract, and compared to the negative control (NC), respectively, at the concentrations of 10, 50 and 100 ㎍ / ml Activity increased to 59.3, 68.9 and 102.9%, respectively.
Claims (4)
Situation mushroom mycelium culturing method excellent in antioxidant and immune function enhancement effect, characterized by cultivating the situation mushroom mycelium in the medium to which the acid extract is added
According to claim 1, the collected powder is washed with water, cut into a suitable size of about 2 ~ 10cm in length and put into the extraction container, the volume of 1 to 30 times, preferably 5 to 15 times the weight of ( w / v%) a solvent selected from water containing purified water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably water, at a temperature of 30 to 120 ° C., preferably at 80 to 100 ° C. for 0.5 to 20 hours, Preferably extracting for 2 hours to 15 hours; Repeating the extraction step about 1 to 10 times, preferably 2 to 7 times; Situation mushroom mycelium culturing method excellent in antioxidant and immune function enhancement effect using the powder extract obtained through the step of filtration concentration and drying
The method of claim 1, as a carbon source, monosaccharides, disaccharides, and food by-products such as ginseng extract, molasses, beer immersion, etc. As a nitrogen source, organic nitrogen source, complex nitrogen source, inorganic nitrogen source, and food byproduct CSL (corn starch leachate) beer yeast Use at least one carbon source and nitrogen source material selected from extracts, cottonseed extracts, whey, etc. The concentration of carbon source and nitrogen source is 2 ~ 3% of carbon source (D-Glucose) and C / N ratio 15: 1 ~ Situation mushroom mycelium culture method excellent in antioxidant and immune function enhancement effect, characterized in that 30: 1 range
The optimum temperature for mycelial growth of the situation mushroom is 25-37? Range, optimum pH for mycelial growth is 5.0 ~ 8.0 range, the aeration amount is 0.5 ~ 2.0 vvm, the stirring speed is 50 ~ 200 rpm excellent anti-oxidation and immune function, characterized in that the mushroom fungus culture method
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110048869A KR20120132646A (en) | 2011-05-24 | 2011-05-24 | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110048869A KR20120132646A (en) | 2011-05-24 | 2011-05-24 | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120132646A true KR20120132646A (en) | 2012-12-07 |
Family
ID=47516154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110048869A Withdrawn KR20120132646A (en) | 2011-05-24 | 2011-05-24 | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20120132646A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103598010A (en) * | 2013-11-12 | 2014-02-26 | 淳安县微生物研究所 | Original ecological imitative wild cultivation method for inonotus sanghuang |
| CN108450231A (en) * | 2018-03-16 | 2018-08-28 | 江西省蚕桑茶叶研究所 | A kind of bionical border expanding propagation method of wild Phellinus |
-
2011
- 2011-05-24 KR KR1020110048869A patent/KR20120132646A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103598010A (en) * | 2013-11-12 | 2014-02-26 | 淳安县微生物研究所 | Original ecological imitative wild cultivation method for inonotus sanghuang |
| CN108450231A (en) * | 2018-03-16 | 2018-08-28 | 江西省蚕桑茶叶研究所 | A kind of bionical border expanding propagation method of wild Phellinus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101269410B1 (en) | Methods of culturing Inonotus obliquus, Phellinus linteus, Ganoderma lucidum, Sparassis crispa and Vegetable Worms using mushroom media | |
| KR100922311B1 (en) | Double Culture Method of Chaga, Situation Mushroom, Ganoderma Lucidum Mushroom, Blossom Mushroom and Cordyceps Sinensis Producing Substances Containing Activated Sugar-related Compounds | |
| CN103263448B (en) | Fermentation bacteria used for fermentation pretreatment to improve extraction of Ginkgo biloba L. leaf flavone and application | |
| KR100848515B1 (en) | Whitening cosmetics containing mushroom mycelium culture as an active ingredient | |
| CN102994305B (en) | Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon | |
| KR20120120515A (en) | Composition and manufacturing method of functional food containing propolis and herbal extract which has antimicrobial, antioxidant, and immunostimulating activity | |
| WA et al. | Bioactive potential of some fascinating edible mushrooms Macrolepiota, Russula, Amanita, Vovariella and Grifola as a treasure of multipurpose therapeutic natural product | |
| HK1249366A1 (en) | Method for producing fermented bamboo extract and immunostimulator | |
| CN101711774A (en) | Application of Phellinus pini polysaccharide extract in preparing medicament for preventing and treating tumor metastasis | |
| CN101233225B (en) | Coriolus versicolor strain, its extract and its application | |
| KR102091084B1 (en) | Composition comprising the extract of Molokia leaf for immune activity | |
| KR102634131B1 (en) | Composition for Liver Function Improvement Comprising Natural Extracts | |
| KR20220020147A (en) | Method for preparing Phellinus linteus mycelia extract or Phellinus linteus mycelia extract powder and composition for enhancing immunity comprising them as an active ingredient | |
| KR101908727B1 (en) | Manufaturing method of morus bark having increased antioxidant substance | |
| KR100838705B1 (en) | Mushroom mycelium cultures, preparation method thereof and use thereof | |
| KR20120132646A (en) | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity | |
| KR20070122234A (en) | Physiologically Active Compositions of Basidiomycetes and Araliaaceae | |
| KR20030086503A (en) | Health care food & beverages for anti-glycosuria by use of fomes fomentarius extract. | |
| CN108208781A (en) | A kind of reparation hepatic injury, the Cordyceps militaris composition and preparation method and application of strengthen immunity | |
| KR20190114400A (en) | Method for producing fermentation products of sanghwang mushroom | |
| CN102987501A (en) | Method for preparing nutrient (liquid) beverages and granules of healthcare food (therapy) products by using extractives of cordyceps militaris and cocoons | |
| KR101817053B1 (en) | Composition for anti-oxidant or anti-cancer or anti-obesity or immune-enhancing containing Codonopsis lanceolata extract | |
| CN107897719B (en) | Natto composite preparation and preparation method thereof | |
| CN118406617B (en) | Application of microorganism composition in fermentation extraction of effective components of schisandra chinensis | |
| KR20220009034A (en) | Mixed culture method of mycelium of 6 species using gastrodia elata blume mediumm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20110524 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |